Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Fulcrum Therapeutics ( (FULC) ).
On February 26, 2025, Fulcrum Therapeutics received a termination notice from MyoKardia regarding their collaboration and license agreement established in 2020. The termination, effective June 26, 2025, will end Fulcrum’s entitlement to milestone payments and royalties, impacting the company’s financial expectations from this partnership.
More about Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for genetically defined diseases. The company specializes in identifying and targeting specific gene expressions related to various medical conditions, including cardiomyopathies.
YTD Price Performance: -25.83%
Average Trading Volume: 714,079
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $193.8M
Learn more about FULC stock on TipRanks’ Stock Analysis page.